Allogene Therapeutics announced on Apr. 13 that its off-the-shelf cell therapy cleared residual disease in a higher proportion of lymphoma patients compared to those receiving standard observation, according to interim results from a pivotal clinical trial.
The findings are significant because they suggest the experimental treatment, cema-cel, could improve outcomes for patients with large B cell lymphoma by reducing the risk of relapse after initial therapy. Allogene said it plans to use these data to seek approval from the U.S. Food and Drug Administration if further study endpoints are met.
The interim analysis included data from 24 patients enrolled in the Phase 2 ALPHA3 trial. Half received cema-cel as consolidation therapy following initial treatment, while the other half were observed without additional intervention. At 45 days, measurable residual disease was cleared in 58.3% of patients treated with cema-cel compared to just 16.7% in the observational group. The company also reported a substantial reduction—97.7%—in plasma circulating tumor DNA among those who received cema-cel, while levels increased by more than a quarter among those only observed.
Safety findings indicated that cema-cel was "very well-tolerated," with no cases of cytokine release syndrome or immune effector cell–associated neurotoxicity syndrome (ICANS) reported among treated patients, according to Allogene. Low-grade infections occurred at similar rates across both groups; however, neurologic events such as headache or dizziness were more common among those given cema-cel but were all low-grade and believed related to preconditioning chemotherapy.
Allogene CEO David Chang said during an investor call that "these early results represent an important step toward redefining first-line large B cell lymphoma management." He added: "Today, many patients are simply observed after first-line therapy, despite remaining at high risk of relapse, and by the time relapse occurs, disease may be more difficult to control." Chang continued: "Our mission is to unlock the transformative potential of CAR-T through our allogeneic platform...democratizing cell therapy...and optimally moving CAR-T earlier in the treatment paradigm where it may have the greatest impact."
Looking ahead, Allogene expects additional interim data on event-free survival—the primary endpoint—in mid-2027 and a primary analysis in 2028 as part of this open-label trial recruiting over 200 participants across more than sixty sites.
